英文名:N-CARBAMYL-L-GLUTAMIC ACID
外观:
纯度:请咨询卖家
分子式:C6H10N2O5
分子量:190.15
最小起售量:10g/20g/100g/1kg
中文同义词:
N-氨基甲酰-L-谷氨酸;N-氨甲酰-L-谷氨酸;N-氨基甲酰-L-谷氨酸(N-氨甲酰-L-谷氨酸);N-氨基甲酰谷氨酸;氨甲酰谷氨酸;N-氨甲酰基谷氨酸;N-氨基甲酰基-L-谷氨酸;N-氨基甲酰谷氨酸(NCG)
英文名称:
N-CARBAMYL-L-GLUTAMIC ACID
英文同义词:
N-CARBAMYL-L-GLUTAMIC ACID;carbamino-l-glutamicacid;carbamylglutamicacid;NCG,N-carbamyl-L-glutamic acid;N-(Aminocarbonyl)-L-Glutamic Acid(Carglumic Acid);N-Carbamyl-L-glutamate;N-Cbm-Glu-OH;N-Carbamyl-L-glutamic
相关类别:
中间体;小分子抑制剂;医药中间体;氨基酸、蛋白质和核酸;原料;医药原料;农用兽用原料;A - H;Amino Acids;Modified Amino Acids;CARBAGLU;原料;有机合成原料;陕西林奈主打产品
沸点
438.1±45.0 °C(Predicted)
密度
1.499±0.06 g/cm3(Predicted)
储存条件
Keep in dark place,Inert atmosphere,2-8°C
酸度系数(pKa)
3.71±0.10(Predicted)
用途
N-氨基甲酰-L-谷氨酸已显示出对氨中毒具有保护作用,并用于治疗急性高氨血症。
生物活性
Carglumic acid (N-Carbamyl-L-glutamic acid) 是 N-乙酰谷氨酸 (NAG) 的功能类似物和氨甲酰磷酸合成酶 1 (CPS1) 的活化剂,用于研究与 N-乙酰谷氨酸合成酶 (NAGS) 缺陷相关的急性和慢性高氨血症。
体外研究
Carglumic acid suppresses cell viability in the pancreatic ductal adenocarcinoma cell lines, triple-negative breast cancer cell lines, hepatoma cell lines, and human non-small cell lung carcinoma cell lines in a dose-dependent manner. The 50% inhibitory concentration (IC 50 ) of Carglumic acid against those cell lines is between 5 and 7.5 mM. The results show that Carglumic acid does not induce complete cell cycle arrest. Instead, there are more sub-G1 cells among Carglumic acid-treated AsPC1 and MDA-MB-231 cells than among untreated cells. In AsPC1 and HPDE-E6E7 cells, the IC 50 s of Carglumic acid are 5 mM and over 10 mM, respectively . In MDA-MB-231 and MCF-12A cells, the IC 50 s of Carglumic acid are 5 mM and 6 mM, respectively.
体内研究
The results show that Carglumic acid, but not the vehicle control, markedly inhibits tumor growth. In the orthotopic pancreatic cancer model, tumor growth inhibition by Carglumic acid on day 21 is 80% (P<0.01). In the orthotopic triple-negative breast cancer model, tumor growth inhibition by Carglumic acid on day 20 is 82% (P<0.01). These results indicate that Carglumic acid suppresses tumor growth in pancreatic cancer and triple-negative breast cancer. On day 20, mean tumor growth inhibition in orally and intravenously treated mice is 55% and 93%, respectively, relative to untreated mice (P<0.01).